The effect of a novel 5HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease

A. Rydzewski, T. Hachiya, T. Urano

Research output: Contribution to journalArticle

Abstract

The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease, was assessed in a pilot study. We investigated 10 patients suffering from Buerger's disease. Sarpogrelate in a dose of 3 × 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. Sarpogrelate induced significant decrease in plasma serotonin concentration starting after 4th week which lasted through 8 weeks of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly alter 2 weeks, and there was also nearly significant increase in whole blood tryptophan concentration (p =0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment and returned to baseline values after 8 weeks. Concentrations of tPA and PAI-1 did not change. There was also no effect, on platelet count, APTT, TT and fibrinogen concentration.

Original languageEnglish
Pages (from-to)47
Number of pages1
JournalFibrinolysis
Volume10
Issue numberSUPPL. 3
Publication statusPublished - 1996

Fingerprint

Thromboangiitis Obliterans
Fibrinolysis
Serotonin
Blood Platelets
Platelet Aggregation
Tryptophan
Serotonin 5-HT2 Receptor Antagonists
Hydroxyindoleacetic Acid
Plasminogen Activator Inhibitor 1
Platelet Count
Adenosine Diphosphate
Fibrinogen
Collagen
Therapeutics
sarpogrelate

ASJC Scopus subject areas

  • Hematology

Cite this

The effect of a novel 5HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease. / Rydzewski, A.; Hachiya, T.; Urano, T.

In: Fibrinolysis, Vol. 10, No. SUPPL. 3, 1996, p. 47.

Research output: Contribution to journalArticle

@article{691d4fdb86504ece8bd05bc3cb065d26,
title = "The effect of a novel 5HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease",
abstract = "The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease, was assessed in a pilot study. We investigated 10 patients suffering from Buerger's disease. Sarpogrelate in a dose of 3 × 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. Sarpogrelate induced significant decrease in plasma serotonin concentration starting after 4th week which lasted through 8 weeks of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly alter 2 weeks, and there was also nearly significant increase in whole blood tryptophan concentration (p =0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment and returned to baseline values after 8 weeks. Concentrations of tPA and PAI-1 did not change. There was also no effect, on platelet count, APTT, TT and fibrinogen concentration.",
author = "A. Rydzewski and T. Hachiya and T. Urano",
year = "1996",
language = "English",
volume = "10",
pages = "47",
journal = "Fibrinolysis",
issn = "0268-9499",
publisher = "Churchill Livingstone",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The effect of a novel 5HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease

AU - Rydzewski, A.

AU - Hachiya, T.

AU - Urano, T.

PY - 1996

Y1 - 1996

N2 - The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease, was assessed in a pilot study. We investigated 10 patients suffering from Buerger's disease. Sarpogrelate in a dose of 3 × 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. Sarpogrelate induced significant decrease in plasma serotonin concentration starting after 4th week which lasted through 8 weeks of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly alter 2 weeks, and there was also nearly significant increase in whole blood tryptophan concentration (p =0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment and returned to baseline values after 8 weeks. Concentrations of tPA and PAI-1 did not change. There was also no effect, on platelet count, APTT, TT and fibrinogen concentration.

AB - The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease, was assessed in a pilot study. We investigated 10 patients suffering from Buerger's disease. Sarpogrelate in a dose of 3 × 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. Sarpogrelate induced significant decrease in plasma serotonin concentration starting after 4th week which lasted through 8 weeks of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly alter 2 weeks, and there was also nearly significant increase in whole blood tryptophan concentration (p =0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment and returned to baseline values after 8 weeks. Concentrations of tPA and PAI-1 did not change. There was also no effect, on platelet count, APTT, TT and fibrinogen concentration.

UR - http://www.scopus.com/inward/record.url?scp=33846703419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846703419&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33846703419

VL - 10

SP - 47

JO - Fibrinolysis

JF - Fibrinolysis

SN - 0268-9499

IS - SUPPL. 3

ER -